(Q54544974)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

1 reference

ChEBI release 2020-05-28

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Kunihiro Yamaoka

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Satoshi Kubo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Kazuhisa Nakano

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Shigeru Iwata

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Kazuyoshi Saito

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Masanobu Ohishi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Hisaaki Miyahara

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Shinya Tanaka

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Koji Ishii

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Hironobu Yoshimatsu

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Yoshiya Tanaka

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

6 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

published in

Arthritis and Rheumatism

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

1790-1798

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

Tyrosine kinases as targets in rheumatoid arthritis

18 January 2020

cites work

1 reference

Tyrosine kinases as targets for the treatment of rheumatoid arthritis

21 January 2018

1 reference

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

21 January 2018

1 reference

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

21 January 2018

1 reference

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis

21 January 2018

1 reference

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 January 2018

1 reference

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

21 January 2018

1 reference

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

Jak3 negatively regulates dendritic-cell cytokine production and survival

21 January 2018

1 reference

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

Synovial fibroblasts spread rheumatoid arthritis to unaffected joints

21 January 2018

1 reference

Inhibitory effect of CD147/HAb18 monoclonal antibody on cartilage erosion and synovitis in the SCID mouse model for rheumatoid arthritis

21 January 2018

1 reference

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.

21 January 2018

1 reference

Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals.

21 January 2018

1 reference

Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts

21 January 2018

1 reference

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients

21 January 2018

1 reference

Synovial mast cells: role in acute and chronic arthritis

21 January 2018

1 reference

Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy

21 January 2018

1 reference

Mast cells express IL-17A in rheumatoid arthritis synovium

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.34329

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22147632%20AND%20SRC:MED&resulttype=core&format=json

release_u2lolgxz75epzkjl7ptfa32rnq

18 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/u2lolgxz75epzkjl7ptfa32rnq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference